Inhibiting the entire receptor complex prevents IL-6 ... inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or disease-modifying antirheumatic drugs.

Bristol–Myers Squibb (BMS) has entered a potential ∼US$1 billion agreement with Alder Biopharmaceuticals involving Alder's lead drug ALD518 ... second-generation IL-6 inhibitors or fast ...

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

For the rest, JAK inhibitors were the most common (1,827 patients; 82% baricitinib [Olumiant]), followed by rituximab (n=1,149), abatacept (n=1,102), and anti-IL-6 drugs (n=887, 80% tocilizumab).

Adverse events from disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis decline by as much as 25% after the drugs are established on the market, according to data published ...